Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in Alzheimer's patients failing donepezil
NCT01478633Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2011
- Primary completion
- Jun 2013
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of galantamine in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Sep 2011; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01478633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01478633.